Episode Details

In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:

• CMV treatment goals 
• CMV treatment and monitoring recommendations
• Role of secondary prophylaxis
• Use of CMV cell–mediated immunity (CMI) monitoring for CMV relapse risk
• Use of CMV CMI for secondary prophylaxis 
• Proposed use of CMV CMI monitoring for secondary prophylaxis
• Incidence and outcomes with antiviral resistance 
• Risk factors for CMV resistance
• When to suspect antiviral resistance 
• Testing for antiviral resistance using genotypic assays
• Outcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virus
• Treatment recommendations for resistant/refractory CMV
• Efficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE study
• Treatment algorithm for resistant/refractory CMV 
• Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV

Faculty:

Raymund Razonable, MD
Professor of Medicine
Program Director, Infectious Diseases Fellowship
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota 

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: 
https://bit.ly/476v2wI

Link to full program: 
https://bit.ly/47lNK2K

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.